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Abstract

Scope: Energy deficit is a common characteristic of neurodegenerative disorders, including Alzheimer's
disease. Adenosine monophosphate activated protein kinase (AMPK) is a key enzyme maintaining energy
balance by regulating the cellular uptake of glucose, β-oxidation of fatty acids, and expression of glucose
transporter 4. Since resveratrol has been shown to increase the activity of AMPK, we hypothesized that it
might influence energy metabolism in a model neuron-like cell line, murine Neuro2a cells.
Methods and results: Resveratrol caused an elevation of adenosine triphosphate (ATP) and guanosine
triphosphate (GTP) in a dose-dependent manner. The highest ATP and GTP levels achieved by treatment
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increases in the total sum of all adenine nucleotides were found upon addition of resveratrol. Despite these
increases in ATP, GTP, and the total adenine nucleotide pool, resveratrol treatment led to a decrease in
glucose consumption and lactate release, suggesting that resveratrol does not increase energy production (e.g.
via AMPK kinase activation) but rather inhibits energy-consuming processes.
Conclusion: Resveratrol increases the levels of ATP and GTP, but without creating an additional glucose
demand.
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Abbreviations
Aβ, Beta-amyloid; AD, Alzheimer’s disease; ADP, Adenosine diphosphate; AMP, Adenosine
monophosphate; AMPK, AMP-activated protein kinase; ATP, Adenosine triphosphate;
CaMKKβ, Calcium/calmodulin-dependent protein kinase kinase-β; DMEM, Dulbecco’s
Modified Eagles Medium; EDTA, Ethylenediamine tetraacetic acid; FBS, Fetal bovine
serum; GDP, Guanosine diphosphate; GTP, Guanosine triphosphate;

HPLC, High

performance liquid chromatography; LKB1, Liver kinase B-1; NAD+, Nicotinamide adenine
dinucleotide;
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Nicotinamide

adenine
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phosphate;
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Tetrabutylammonium hydrogen sulphate; ULK1, unc-51-like kinase-1; WVL, Wave length.
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Abstract
Scope: Energy deficit is a common characteristic of neurodegenerative disorders, including
Alzheimer's disease. AMP-activated protein kinase is a key enzyme maintaining energy
balance by regulating the cellular uptake of glucose, β-oxidation of fatty acids and expression
of glucose transporter 4. Since resveratrol has been shown to increase the activity of AMPK,
we hypothesized that it might influence energy metabolism in a model neuron-like cell line,
murine Neuro2a cells.
Methods and Results: Resveratrol caused a significant elevation in the levels of the energyrich carriers ATP and GTP in a dose-dependent manner. The highest ATP and GTP levels
achieved by treatment with resveratrol were 70.3 ± 8.2 nmol/mg protein (1.9 fold of control
cells) and 27.2 ± 4.0 nmol/mg protein (1.7 fold of control cells), respectively, when cells were
treated with 100 µM resveratrol for 6 h. Interestingly, substantial increases in the total sum of
all adenine nucleotides were found upon addition of resveratrol. Despite these increases in
ATP, GTP and the total adenine nucleotide pool, resveratrol treatment led to a pronounced
decrease in glucose consumption and lactate release, suggesting that resveratrol does not
increase energy production (e.g. via AMPK kinase activation) but rather inhibits energy
consuming processes.
Conclusions: Resveratrol increases the levels of free high-energy nucleotides, including ATP
and GTP, but without creating an additional glucose demand.
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Introduction
Alzheimer's disease (AD) is the most common form of dementia in the elderly [1], resulting in
gradually impaired memory, learning and communication skills [2]. With the use of positron
emission tomography, it has been shown that AD brains display evidence of a reduction in
glucose metabolism even in the early stages of the disease [3, 4]. For example, findings by
Sakamoto and colleagues [5] indicated that both early-onset and late-onset AD patients show
marked hypo-metabolism in the bilaterally parieto-temporal regions of the brain, compared to
the age-matched control subjects. Therefore, diminished brain energy metabolism is
postulated as one of the contributing factors for neuronal dysfunction and cell death and the
resulting cognitive deficits in AD [6, 7].

Adenosine triphosphate (ATP), a multifunctional high-energy molecule is present in all
metabolically active cells [8]. Neuronal cells in particular have a high metabolic activity and
are highly dependent on energy production via glucose metabolism for active transport and
maintenance of ion homeostasis [9, 10]. Specifically, high levels of ATP are required to
recover Na+ and K+ distribution across the plasma membrane, providing an electrochemical
gradient necessary for maintenance of the resting membrane potential and control of osmotic
balance [11], as well as for the formation and release of neurotransmitters and synaptic
function [12, 13].

A progressive reduction in ATP levels relating to the degree of neurodegeneration in the AD
brain has been identified in sporadic AD patients [14, 15]. According to the study of Hoyer
[14], a decrease in the cerebral ATP generation rate was found to range from at least 7% in
incipient early-onset AD to approximately 19% in incipient late-onset AD, while more than
50% ATP generation rate was reduced in stable advanced AD. In addition, Sims and
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colleagues [15] also have shown that ATP levels in the neocortical tissue of AD brains were
significantly lower than in healthy controls.

AMP-activated protein kinase (AMPK), one of the key enzymes regulating cellular energy
homeostasis, is a promising target for the treatment of metabolic disorders [16, 17]. AMPK is
a crucial cellular energy sensor. Once activated by falling energy status, it promotes ATP
production by increasing the activity or expression of proteins involved in catabolism while
conserving ATP by switching off biosynthetic pathways. Activated AMPK suppresses ATP
consumption pathways, including cell growth, protein synthesis, fatty acid synthesis and
ribosome biosynthesis, whereas stimulating ATP generation pathways such as glucose uptake,
glycolytic flux, fatty acid oxidation and mitochondrial biogenesis [18, 19]. AMPK activation
plays a protective role in metabolic stress conditions, such as ischemia, hypoxia, oxidative
stress and starvation [18, 20, 21] and is modulated by exercise and dietary hormones,
including leptin and adiponectin [22, 23]. AMPK activation facilitates dietary food intake
regulated by the hypothalamus [22], glucose uptake and fatty acid oxidation in heart and
skeletal muscle [24, 25], whilst it suppresses fatty acid and cholesterol synthesis in the liver
[26].

Resveratrol (trans-3,4’,5-trihydroxystilbene), a naturally occurring polyphenol, is present in
the skin of red grapes, some fruits and herbs such as Polygonum cuspidatum at high levels
and possesses strong antioxidant properties [27]. Resveratrol has been found to activate
AMPK in neuroblastoma cells and primary neurons in vitro as well as in the brain by
activating calcium/CaMKKβ/AMPK signaling pathways [28, 29].
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In this study, we have investigated the effect of resveratrol on neuronal energy levels, and
therefore initially measured its effects on levels of ATP and GTP. Further, the effect of
resveratrol on glucose consumption and lactate release of Neuro2a cells was investigated in
order to determine whether the observed pro-energetic effect of resveratrol was caused by an
increase in aerobic glucose consumption. Together our data identifies a new role for
resveratrol, increasing the total adenine nucleotide content and inhibiting energy consuming
processes in Neuro2a cells.
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Materials and Methods
Materials
The murine neuroblastoma Neuro2a cell line was obtained from ATCC (South Granville,
Australia). All cell culture materials were from Invitrogen (Mulgrave, Australia). Coomassie
Blue Brilliant G-250 powder for Bradford assay was from Amresco (Astral, Sydney,
Australia). Chromatography grade acetonitrile was from Merck (Kilsyth, Australia). HPLC
buffers were prepared with ultra-pure water filtered through Milli-Q system (Millipore, North
Ryde, Australia). Trans-Resveratrol was provided by Nutrafur (Alcantarilla, Spain). All other
reagents and chemicals were from Sigma-Aldrich (Castle Hill, Australia).

Cell maintenance
Neuro2a cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 25
mM glucose, supplemented with 5% heat-inactivated foetal bovine serum (FBS), 2 mM Lglutamine (Glutamax), antibiotics (200 U/mL penicillin, 200 μg/mL streptomycin) and
fungicide (2.6 μg/mL Fungizone). The cell line was maintained in 5% CO2 at 370C and
passaged every 3-4 days in 75 or 175 cm2 tissue culture flasks. For experiments, Neuro2a
were harvested by cell scraper, counted with Trypan blue and seeded in 12-well plates at a
density of 0.55x106 cells/well in 2 mL DMEM containing 2% FBS and incubated for 24 hours
before treatment with resveratrol.

Treatment of Neuro2a cells with resveratrol
A stock solution of resveratrol (100 mM) was prepared immediately before use by dissolving
in absolute ethanol. Neuro2a cells were incubated with medium containing resveratrol at a
range of concentrations (12.5, 25, 50, 75, 100 µM) and in a final concentration of 0.1%
ethanol. Control cells were treated with medium containing 0.1% ethanol. Intracellular energy
7

levels were measured after 1, 6, 12, 24 and 48 h incubation with resveratrol. At each time
point, the cells were washed three times with phosphate buffered saline, extracted with icecold HClO4 0.5M and neutralized with ice-cold K2CO3 2M to pH 7. The supernatants were
stored at -80 oC prior to analysis by HPLC. The cell pellets were dissolved in NaOH 1M, then
protein content was determined by the Bradford assay. At the time points of 24 h and 48 h, 1
mL medium from each well was collected and centrifuged at 1000 xg for 3 min and the
supernatant was frozen at -80 oC prior to glucose and lactate assay.

Measurement of intracellular nucleotide levels
50 μL supernatant of each sample was injected into the stationary phase and analyzed by
gradient ion-pair reversed-phase HPLC [30]. Briefly, the mobile phase was composed of
buffer A (100 mM KH2PO4, 8 mM TBA, pH 6.0) and buffer B (100 mM KH2PO4, 8 mM
TBA, 30% acetonitrile (v/v), pH 6.0) at 1.5 mL/min flow rate. The stationary phase system
was a Supelcosil-LC-18-T column (150x4.6 mm, 3 µm) and a Supelguard LC-18-T Guard
Column (Supelco, Castle Hill, Australia). Nucleotides were detected at the wavelength of 254
nm with a photodiode array PDA ICS-3000 detector (Dionex, Lane Cove, Australia). Stock
solutions of 5 nucleotides of interest including ATP, ADP, AMP, GTP and GDP were
prepared in KH2PO4 0.1M pH 7.0 and then mixed together to give the top concentration of
100 µM for each nucleotide. This mixture was then diluted in KH2PO4 0.1M, pH 7.0 by a
factor of 2 to form standard solutions of decreasing concentration from 100 to 1 µM.
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Determination of glucose levels in media
The medium samples were defrosted and diluted 1:8 with distilled water. Glucose
concentration in each sample was determined by an enzymatic reaction previously described
[31] with a slight modification. 20 µL of each diluted sample was added to each well of a flat
bottom 96-well plate in duplicate, followed by 180 µL of a reaction mixture composed of 1
U/mL hexokinase/glucose-6-phosphate dehydrogenase, 2 mM NADP+, 6 mM ATP, 3 mM
MgSO4 in 0.3 M triethanolamine buffer, pH 7.6. After being incubated for 2 hours at room
temperature, absorbance at 340 nm was measured using a microplate reader (BMG Labtech,
Mornington, Australia). A standard curve of glucose in the range from 0 to 3 mM was fit with
a linear regression.

Determination of lactate levels in media
The medium samples were defrosted and diluted 1:8 with distilled water. Lactate
concentration in each sample was determined by an enzymatic reaction previously described
[32] with a slight modification. 20 µL of each diluted sample was added to each well of a flat
bottom 96-well plate in duplicate, followed by 180 µL of a reaction mixture consisting of 50
U/mL lactate dehydrogenase and 10 mM NAD+ in a 0.2 M hydrazine – 0.2 M glycine buffer
containing 5 mM EDTA, pH 9.5. After being incubated for 1 hour at 37 0C and 20 minutes
subsequently at room temperature, absorbance at 340 nm was measured with a microplate
reader (BMG Labtech, Mornington, Australia). A standard curve of lactate in the range from
0 to 3 mM was fit with a linear regression.

Determination of total protein
Total protein content was assessed by Bradford assay [33]. Bradford solution was made by
dissolving 100 mg Coomassie Blue Brilliant G-250 in 50 mL ethanol 100% and 100 mL
9

phosphoric acid 85%, then diluted to 1L with double distilled water and filtered through
Whatman No.1 filter paper. To evaluate total protein amount of cell lysates, 10 µL of each
sample was added to each well of 96-well flat bottom plate in duplicate, followed by 200 µL
Bradford solution. Absorbance was measured at 595 nm using a microplate reader (Bio-Rad,
Gladesville, Australia). A standard curve in the linear range was constructed by dissolving
bovine serum albumin in a range of 0.05 to 0.5 mg/mL in NaOH 1M.

Neutral Red uptake assay for cell viability assessment
To determine cell viability, the incubation medium was removed from wells and replaced
with Neutral Red medium (50 µg/mL). After being incubated for 2 hours at 37°C and 5%
CO2, Neutral Red medium was removed from the cells and the cells were washed once with
phosphate buffered saline and extracted with destaining solution (50% absolute ethanol, 49%
distilled water and 1% glacial acetic acid). The plates were shaken on a micro-plate shaker for
at least 10 minutes until the Neutral Red was completely removed from cells. The absorbance
was measured at 540 nm with a microplate reader (Bio-Rad, Gladesville, Australia). Values
were expressed as a percentage of untreated control cells after subtracting mean blank
readings in the absence of cells.

Statistics
Data were analysed and displayed in figures using GraphPad Prism 5. Values presented are
the mean of 3 independent experiments in duplicate and error bars denote standard error of the
mean (SEM). Significant differences were assessed by Student’s t-test for comparison
between 2 groups or one-way ANOVA with Dunnett’s multiple comparison test for
comparison of 3 or more groups, and significance is shown as * p<0.05, ** p<0.01 and ***
p<0.001.
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Results
Effect of resveratrol on proliferation of the Neuro2a cell line
The cell number and the total protein content at each timepoint and at each resveratrol
concentration was determined to allow us to normalize the nucleotide phosphate
concentrations in the later experiments. Therefore, Neuro2a cells were incubated with
different concentrations of resveratrol (ranging from 12.5 μM to 100 μM) for 24 and 48 h.
The number of cells at each time point was determined using a phagocytosis based cell
viability assay (Neutral Red) and compared to the number of cells present at 0h. The number
of untreated Neuro2a cells increased to 151% (at 24 h) and 166% (at 48 h). With increasing
resveratrol concentrations, proliferation decreased in a dose dependent manner (Fig. 1A).
Total protein content followed a similar dose-response curve (Fig. 1B). At 100 µM
resveratrol, cell numbers at 24 and 48 h fell below the cell number at the starting point (Fig.
1A,B). For this reason, all following experiments, used a dose range of 12.5 μM to 100 μM
resveratrol, whereby 12.5 μM was considered as the “highest non-toxic” concentration, 50
μM as an “antiproliferative” and 100 μM as a “cytotoxic” concentration.

Resveratrol significantly increases the levels of the high-energy nucleotides ATP and
GTP in a dose-dependent manner
ATP and GTP are the most important energy carriers in living cells. To investigate the effects
of resveratrol on the concentrations of these nucleotides, Neuro2a cells were treated with
resveratrol at concentrations ranging from 0 to 100 µM. ATP and GTP levels were
determined after 1, 6, 12, 24 and 48 h of incubation.
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In the untreated control cells, the levels of ATP and GTP decreased during the incubation
period, from approximately 42.0 nmol ATP and 20.3 nmol GTP/mg protein (1 h) to 26.0 nmol
ATP and 13.2 nmol GTP/mg protein (24 h) and drastically deteriorated at 48 h, where ATP
and GTP levels were approximately 11.4 and 7.0 nmol/mg protein, respectively (Fig. 4A, 4B).

The addition of resveratrol led to a significant elevation in intracellular ATP levels, compared
to untreated controls, in a dose-dependent manner (Fig. 2, 4A). This effect could be observed
after 1 h of treatment and these increases lasted up to 48 h (Fig. 4A). The highest levels of
ATP observed were 70.3 ± 8.2 nmol/mg protein (1.9 fold higher than in non-treated control
cells), measured at the 6 h time-point and at a concentration of 100 µM resveratrol (Fig. 2,
4A).

Resveratrol did also increase GTP levels at all time points up to 48 h (Fig. 4B). The highest
GTP level observed after treatment with resveratrol was 27.2 ± 4.0 nmol/mg protein (equal to
1.7 fold higher than non-treated control cells), which was also reached at 6 h following
treatment with 100 µM resveratrol (Fig. 2, 4B).
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Resveratrol leads to an increase in the levels of AMP and GDP
ADP, AMP and GDP are low-energy nucleotides derived from the hydrolysis of one or two
high energy phosphate bonds of ATP and GTP. We examined their levels in Neuro2a cells
after addition of resveratrol to investigate the effects of resveratrol on energy metabolism. If
activation of AMPK would be the major mode of action of resveratrol, one would expect an
increase in energy charge, evident by a decrease in the concentration of these low energy
nucleotides compared to ATP and GTP.

Surprisingly, resveratrol also caused a dose-dependent increase in ADP and AMP levels in
Neuro2a cells as early as 1 h and up to 24 h after treatment. No significant changes in GDP
levels could be observed between the non-treated control and resveratrol-treated cells except
at 48 h (Fig. 3).

At 48 h (when nutrient levels in control cells appear to be depleted), AMP and GDP levels of
the non-treated controls dramatically increased whilst ATP and GTP levels markedly declined
(compare Fig. 3, 4 and 5). It is possible that some essential nutrients in the cell culture were
exhausted due to proliferation and therefore cells could not sufficiently replenish ATP and
GTP from AMP, ADP and GDP. Therefore, a large amount of ATP was hydrolyzed to the
low-energy phosphate AMP (Fig. 5B), and GTP was hydrolysed to GDP (Fig. 5C) in
untreated Neuro2a cells. Resveratrol treatment significantly lowered the levels of low-energy
nucleotides AMP and GDP levels by more than 50% in Neuro2a cells after 48 h, compared to
control values (Fig. 5B, 5C).
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Resveratrol significantly increases the total pool of adenine nucleotides
We examined the effect of resveratrol on the total adenine nucleotide content in Neuro2a
cells. The results showed that the sum of adenine nucleotides in untreated control cells also
decreased over the 48 h incubation period consistent with the expected reduction in ATP
levels and ranged from 49.3  5.3 nmol/mg protein (1 h) to 25.1  2.4 nmol/mg protein (48 h)
(Table 1).

In cells treated with resveratrol, a substantial elevation in total adenine nucleotide levels of
Neuro2a, compared to control cells was observed in a dose-dependent manner. This effect
was apparent at all experimental time-points. The highest value of total adenine nucleotide
content obtained after treatment with resveratrol was 81.4  8.6 nmol/mg protein (equivalent
to 1.8 fold of the control cells), at 6 h following treatment with 100 µM resveratrol.

Resveratrol does not change the cellular energy charge potential (ECP) ratio during the
stages of sufficient nutrition, but improves that ratio at the stages of starvation
As first proposed by Atkinson and Walton in 1967 [34], the energy charge potential (ECP) or
adenylate energy charge (AEC) is an index used to measure the energy status of biological
cells. ECP is calculated by the following equation: ECP (%) = (ATP + ½ ADP) x 100/ (ATP
+ ADP + AMP). In theory, ECP can vary from 0% (all AMP) to 100% (all ATP); however,
ECP is normally maintained in the range of 70% to 100% in healthy cells and tissues that are
provided with sufficient nutrition and oxygenation [35, 36]. Thereupon, ECP can be seen as
an indicator of “well-being” status of cells and organisms [37].

We assessed the effect of resveratrol on ECP during 48 h experiments. The results show that
there were no statistical differences between ECP of untreated cells and cells treated with
14

resveratrol during the first 24 hours, with ECP remaining at high levels (> 80%) suggesting a
balanced metabolic status in the cells (Fig. 6A). Previous experiments suggested that 48 h of
resveratrol led to a marked increase in the low-energy nucleotide AMP and a substantial
decrease in the high-energy carrier ATP (Fig. 3, 4, 5) since the nutrient source in the culture
medium was consumed and exhausted over the time of incubation, resulting in a drop of ECP.
Hence, we investigated whether resveratrol could reverse this phenomenon. At the 48 h timepoint, ECP drastically reduced to under 70% in control cells, indicating energy depletion
occurring (Fig. 6B). Resveratrol, however, suppressed this phenomenon as it elevated the
ECP to over 80% at all concentrations of resveratrol treatment from 12.5 µM to 100 µM (Fig.
6B).

Resveratrol induces pronounced decreases in glucose consumption by Neuro2a cells
Because glucose is the major energy source for living cells to produce ATP and GTP [38], we
investigated whether the mechanism behind these resveratrol-induced increases in highenergy phosphates was due to an increase in glucose uptake.

Glucose consumption or glucose uptake was calculated based on the decrease in glucose
concentration in the media after 24 h or 48 h. The outcomes show that although resveratrol
treatment resulted in a significant increase in ATP and GTP, this was not accompanied by
higher glucose consumption (Table 2 and Table 3). During the first 24 hours, resveratrol at
the concentrations of 12.5 µM, 25 µM, 50 µM, 75 µM and 100 µM caused a reduction in
glucose consumed by Neuro2a cells to 20%, 30%, 43%, 55% and 60%, respectively, whereas
a reduction in cell viability was only 4%, 9%, 23%, 30% and 48%, respectively (Table 2).
Similarly, resveratrol-induced decreases in glucose consumption by the Neuro2a cell
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population were also observed following the 48 h treatment with resveratrol (Table 3).
Therefore, the values of glucose consumption normalized to cell viability of Neuro2a cells
were considerably lower than controls. These data therefore suggest that despite resveratrolinduced ATP and GTP increases, resveratrol decreased glucose consumption by Neuro2a
cells.

Resveratrol induces a downward trend in lactate production by Neuro2a cells
The culture DMEM constituents in the study did not contain lactate (Invitrogen, Catalogue
11960). Lactate accumulated in the media of control cells measured 11.0 ± 0.6 mM and 26.6
± 1.2 mM after 24 and 48h, respectively. Neuro2a treated with resveratrol showed a slow
decrease in lactate release during the first 24 h and a more pronounced decrease in the next 24
h (Table 2 and Table 3). The values of lactate release or glucose production in cells treated
with resveratrol were expected to be higher than cell viability (the values of end-point) since
the population of cells treated with high concentrations of resveratrol was decreased over time
due to the toxicity of the compound. During 48 h treatment, however, the data indicate that
resveratrol at the concentrations of 12.5 µM and 25 µM caused a reduction in lactate
production by the Neuro2a population by around 20% and 29%, respectively whereas the
reduction in cell viability was only 3% and 19% (Table 3). Therefore, these results suggest
that there was a downward trend in lactate released by cells incubated with resveratrol. One
reason could be that resveratrol might improve mitochondrial function; thereby more lactate
could enter the next steps (citric acid cycle and oxidative phosphorylation) and produce a
boost of ATP. This hypothesis is in agreement with other studies that also reported resveratrol
to be able to protect cells from mitochondrial dysfunction and to increase the number of
mitochondria [45-47].
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Discussion
Energy depletion has been implicated as an early hallmark of AD occurring even prior to
clinical symptoms and consistently in association with the progression of the disease in
numerous studies [4, 14]. Viewed from this perspective, resveratrol – a natural antioxidant
having the capability of stimulating AMPK – was tested for its effects on levels of important
nucleotides. Resveratrol showed a strong ability to elevate high energy carrier ATP in the
neuronal culture model Neuro2a cell line. This work also provides the new angle of
resveratrol in a capability of increasing GTP levels which has not been reported in the
literature so far. Although GTP is less abundant than ATP, GTP plays an important role in
specific processes including microtubule assembly [48], a defective process found in AD
brains [49]. Furthermore, resveratrol reversed a drop in ECP due to nutrition-restricted
conditions at the late stages of the experiments, from approximately 60% of untreated cells to
higher than 80% even at low concentrations of resveratrol treatment which did not cause
significant reduction in cell viability.
At low doses (< 10μM), the literature suggests that resveratrol protects cells from
mitochondrial dysfunction [1-3], increases the number of mitochondria [4] and induces the
disposal of existing dysfunctional mitochondria [5-7]. High doses of resveratrol (>100 μM)
induce apotosis [8], resulting in loss of mitochondrial membrane potential [9, 10].
Furthermore our experiments demonstrated that resveratrol treatment resulted in consistent
increases in total adenine nucleotide levels. Since the sum of adenine nucleotides has been
found to be markedly reduced in the tissue from AD patients obtained at diagnostic
craniotomy compared to control values [15], these findings in our study might provide a
promising clue of the effect of resveratrol on the improvement of total adenine nucleotide
contents in AD brain in vivo.
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Energy depletion is likely to play a major role in neurodegenerative disease, including AD
and resveratrol may therefore be protective in these instances. However our results suggest
that administering the correct dose would be important Resveratrol has an ability to increase
ATP levels at a concentration of 12.5 µM, a concentration which did not affect cell viability.
However, currently it would be difficult to achieve precise concentrations of 12.5 µM in
human plasma with oral administration. Research on healthy volunteers who administrated up
to 5 g oral resveratrol/single dose (10 times higher than normal oral dose of resveratrol)
indicated that peak plasma levels of resveratrol were only 2.4 μM, occurred 1.5 h post-dose
[50]. Therefore, in order to provide concentrations able to increase intracellular ATP levels as
such 12.5 µM resveratrol in human plasma, resveratrol given by injection may be required.

Despite resveratrol-induced steady increases in ATP and GTP levels, there is no upward trend
found in glucose content consumed by Neuro2a cells and even a substantial reduction in
glucose uptake was identified with resveratrol treatment. In combination with the results of
lactate production which showed that Neuro2a cells treated with resveratrol had a tendency to
decrease lactate release, suggesting the role of resveratrol to restrain aerobic glycolysis – an
ineffective way to produce ATP from glucose. The study of Vlassenko et al. [51], conducted
on living AD patients and healthy volunteers, indicates that high levels of aerobic glycolysis
correlate with the -amyloid (Aβ) deposition in individuals with AD. Since AD is found to
link to aerobic glycolysis in vivo [51, 52], compounds able to suppress aerobic glycolysis,
such as resveratrol, can be seen as a potential approach for the AD treatment.

In a recent study [53], resveratrol is also demonstrated to reduce both glucose uptake and
lactate production, leading to decreased cellular proliferation in various cancer cell lines such
as HeLa, HepG2 and MCF-7. Suppression of aerobic glycolysis may account for the

18

anticancer properties of resveratrol [53] because cancer cell metabolism is characterized by
increased glucose uptake and lactate production to provide cancer cells with an advantage to
grow even in low-oxygen environments within tumors [54].

If aerobic glycolysis is suppressed, more pyruvate can enter the next metabolic steps where an
abundance of ATP can be generated in the mitochondria and no further glucose consumption
is required. The powerhouse of energy production, mitochondrial function and number
primarily impact on the supply of ATP [55]. Numerous studies in the literature also reported
resveratrol protected cells from mitochondrial dysfunction [45-47]. Interestingly, resveratrol
was found to increase the number of mitochondria in various cell lines and tissues, such as in
Neuro2a cells [28], endothelial cells [56] and muscle [45]. In cultured human coronary arterial
endothelial cells, resveratrol up-regulated protein expression of electron transport chain
components, enhanced mitochondrial DNA content and mitochondrial mass, activated
mitochondrial biogenesis factors (peroxisome proliferator-activated receptor- coactivator-1α
PGC-1α, nuclear respiratory factor-1 NRF-1, mitochondrial transcription factor-A mtTF-A)
[56]. Knockdown of NAD+-dependent protein deacetylase SIRT1 prevented resveratroltriggered mitochondrial biogenesis, suggesting that resveratrol elevated mitochondrial content
in a SIRT1-dependent manner [56].

In neurons, however, resveratrol stimulated mitochondrial biogenesis in an AMPK-dependent
manner through its upstream LKB1 pathway, but independent of SIRT1 [28]. AMPK
activation facilitates not only the generation of new mitochondria, but also the destruction of
defective mitochondria [57]. Activated AMPK promotes the biogenesis of new mitochondria
through effects on PGC-1α-dependent transcription and simultaneously induces the disposal
of existing dysfunctional mitochondria via serine/threonine-protein kinase ULK1-dependent
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mitophagy [57-59]; therefore explaining the manipulation of resveratrol in ATP production
occurring in the mitochondria. It is well-established that AMPK activation is capable of
switching off the ATP consumption and switching on the ATP production in cells. However,
in the case of resveratrol, the findings of our experiments also found that it also up-regulates
the levels of GTP, apart from ATP.

However, AMPK activation would rather improve energy charge than increase the total
nucleotide pool. There are alternative reasons which may account for the increase of the total
nucleotide pool caused by resveratrol. Resveratrol has been found to arrest cell growth and
cell cycle progression, which are energy-consuming progresses [61, 62]. Resveratrol
promotes DNA synthesis inhibition and a strong but reversible S-phase delay by the
activation of proteins controlling cell cycle progression cyclin-dependent kinase 2 and
checkpoint kinase 2 as well as the inhibition of phosphatidylinositol 3′-kinase/Akt signaling
pathway [61]. If the total numbers of cell division are expected to remain constant in a given
organism, slowing down of the cell cycle selectively in the S-phase would result in agingdelay of this organism and may explain the effect of resveratrol on lifespan prolongation [61].

In conclusion, a growing body of literature has suggested a possible beneficial role of
resveratrol for AD. Experiments on AD transgenic mouse models with oral resveratrol
administration showed that A levels and deposition were reduced in the cortex compared to
controls [29]. Resveratrol pronouncedly decreased the amounts of secreted and intracellular
A peptides generated from different cell lines by facilitating intracellular degradation of Aβ
involving the proteasome [63]. In addition, resveratrol can cross through the intact bloodbrain barrier to exert its strong antioxidant properties against oxidative stress in AD [64].
Apart from those benefits of resveratrol against amyloid plaques or oxidative stress as
20

therapeutic targets reported in the literature, this study represents a fruitful new mechanism of
resveratrol on improvement of cellular energy levels and supports the potential of low
concentrations of resveratrol for the prevention and treatment of AD.
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Figure Legends

Fig. 1: Cell viability after resveratrol treatment. Toxicity of resveratrol on cell viability
appeared from the concentration of 25 µM in both 24h and 48h time-points. Values = Mean ±
SEM (3 experiments). Significant differences were assessed by one-way ANOVA with
Dunnett’s multiple comparison test, * p<0.05, ** p<0.01 and *** p<0.001.

Fig. 2: Chromatograms of Neuro2a extracts after treatment with 0 µM (A), 12.5 µM (B) and
100 µM (C) resveratrol at 6 h time-point. The peak areas of each compound were integrated
and compared to a standard curve to calculate the individual concentrations of nucleotides.

Fig. 3: Chromatograms of Neuro2a extracts after treatment with 0 µM (A), 12.5 µM (B) and
100 µM (C) resveratrol after 48 h. The peak areas of each compound were integrated and
compared to a standard curve to calculate the individual concentrations of nucleotides.

Fig. 4: Intracellular ATP and GTP levels of Neuro2a cells after treatment with resveratrol.
ATP (A) and GTP levels (B), normalised to protein contents, were significantly increased in
cells treated with resveratrol in all experimental time-points from 1 h to 48 h. Data are the
mean ± SEM of 3 independent experiments in duplicate. Significant differences were assessed
by one-way ANOVA with Dunnett’s multiple comparison test and shown as * p<0.05, **
p<0.01 and *** p<0.001.
Fig. 5: Effect of resveratrol on intracellular ADP (A), AMP (B) and GDP (C) levels of
Neuro2a cells. Nucleotide levels were normalised to protein concentration and data are the
mean ± SEM of 3 independent experiments in duplicate. Significant differences were assessed
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by one-way ANOVA with Dunnett’s multiple comparison test and shown as * p<0.05, **
p<0.01 and *** p<0.001.

Fig. 6: ECP ratios of Neuro2a cells after 1 - 48 h treatment with resveratrol. (A) ECP
maintained at the high level over 80% during first 24 h in cells with or without resveratrol
addition. (B) At 48 h time-point, ECP fell to under 70% in untreated cells whilst resveratrol
suppressed the decrease in ECP and elevated it to over 80%. Values = Mean ± SEM (3
experiments); * p<0.05, ** p<0.01 and *** p<0.001.
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